Showing 5971-5980 of 8181 results for "".
- Study: Strontium Cream Could Help Manage Pruritus in HShttps://practicaldermatology.com/news/Study-Strontium-Cream-Could-Help-Manage-Pruritus-HS/2475142/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to new research published in the Journal of Clinical and Aesthetic Dermatology. Statistical analysis of baseline and 1-week post-intervention surveys amon
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- INT for Melanoma 'Coming Very Fast,' Dr. Joel Claveau Says at Noah Worcester Meetinghttps://practicaldermatology.com/news/INT-Melanoma-Coming-Very-Fast-Dr-Joel-Claveau-Says-Noah-Worcester-Meeting/2475044/The next big thing in melanoma treatment may be individualized neoantigen therapy (INT)—according to Joel Claveau, MD, in a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec. “It’s almost rocket science, but it’s really coming very fast,” Dr. Claveau
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi
- Probiotic for Oily and Acne-Prone Skin Gets US Patenthttps://practicaldermatology.com/news/Probiotic-Oily-Acne-Prone-Skin-Gets-US-Patent/2474976/A probiotic for managing oily, acne-prone skin was awarded US Patent No. 12,194,068, Codex Labs announced. In an independent clinical trial at Integrative Skin Solutions Research involving 18 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Cod
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- From WHA78: Skin Diseases Are a Global Public Health Priorityhttps://practicaldermatology.com/news/wha78-skin-diseases-are-a-global-public-health-priority/2474881/In what was termed a historic decision at the 78th World Health Assembly (WHA78) in Geneva, Member States unanimously adopted a resolution declaring skin diseases a global public health priority, according to a press statement.
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://practicaldermatology.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.